Pharmacokinetic and bioequivalence study of new S-1 capsule in Chinese cancer patients.

In conclusion, the newly developed generic S-1 showed similar pharmacokinetics to those of an original brand-name S-1 in cancer patients, thereby indicating bioequivalence. Furthermore, both treatments were well tolerated, suggesting that the cost-effective generic S-1 should be considered as a feasible option when treating patients.
PMID: 32470574 [PubMed - as supplied by publisher]

Source: European Journal of Pharmaceutical Sciences - May 25, 2020 Category: Drugs & Pharmacology Authors: Chen Y, Jiang Y, Qu J, Wang Q, Bai Y, Shi J, Shi Y, Chen X, Yang N, Heng J, Li K Tags: Eur J Pharm Sci Source Type: research